Abstract
Genetic variants identified through genome-wide association studies (GWAS) are typically non-coding and exert small regulatory effects on downstream genes, but which downstream genes are ultimately impacted and how they confer risk remains mostly unclear. Conversely, variants that cause rare Mendelian diseases are often coding and have a more direct impact on disease development. We demonstrate that common and rare genetic diseases can be linked by studying the gene regulatory networks impacted by common disease-associated variants. We implemented this in the ‘Downstreamer’ method and applied it to 44 GWAS traits and find that predicted downstream “key genes” are enriched with Mendelian disease genes, e.g. key genes for height are enriched for genes that cause skeletal abnormalities and Ehlers-Danlos syndromes. We find that 82% of these key genes are located outside of GWAS loci, suggesting that they result from complex trans regulation rather than being impacted by disease-associated variants in cis. Finally, we discuss the challenges in reconstructing gene regulatory networks and provide a roadmap to improve identification of these highly connected genes for common traits and diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
O.B.B. is supported by an NWO VIDI grant awarded to I.H.J (no. 016.171.047). I.H.J. is supported by a Rosalind Franklin Fellowship from the University of Groningen and an NWO VIDI grant (no. 016.171.047). L.F. is supported by grants from the Dutch Research Council (ZonMW-VIDI 917.14.374 and ZonMW-VICI to L.F.) and by an ERC Starting Grant, grant agreement 637640 (ImmRisk) and through a Senior Investigator Grant from the Oncode Institute. P.D. is supported by an NWO, ZonMW-VENI grant (no. 9150161910057).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added URL to supplementary data on figshare
Data Availability
Software and scripts are available for download at: https://github.com/molgenis/systemsgenetics/tree/master/Downstreamer A manual for Downstreamer is available at: https://github.com/molgenis/systemsgenetics/wiki/Downstreamer All RNA-seq data used in the main analysis are publicly available in the European Nucleotide Archive.
